Details of the Drug

General Information of Drug (ID: DMKV4NL)

Drug Name
Flavoxate
Synonyms
Bladuril; Flavossato; Flavoxato; Flavoxatum; Urispas; Flavossato [DCIT]; Flavoxate HCI; Flavoxate HCL; Spasuret hydrochloride; AK 123; Bladderon (TN); Bladuril (TN); DW-61; Flavoxate (INN); Flavoxate [INN:BAN]; Flavoxato [INN-Spanish]; Flavoxatum [INN-Latin]; Urispas (TN); Uritac (TN); Zopyran-8-carboxylate; Beta-piperidinoethyl 3-methylflavone-8-carboxylate; Piperidinoethyl-3-methylflavone-8-carboxylate; 1-Piperidinoethanol, 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylat; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-Piperidinoethyl-3-methyl-4-oxo-2-phenyl-4H-1-ben; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate; 2-piperidinoethyl 3-methylflavone-8-carboxylate; 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester
Indication
Disease Entry ICD 11 Status REF
Dysuria MF50.7 Approved [1]
Nocturia MF55 Approved [1]
Suprapubic pain MG30-MG3Z Approved [1]
Urgency N.A. Approved [1]
Priapism N.A. Investigative [2]
Therapeutic Class
Parasympatholytics
Affected Organisms
Humans and other mammals
ATC Code
G04BD02: Flavoxate
G04BD: Drugs for urinary frequency and incontinence
G04B: UROLOGICALS
G04: UROLOGICALS
G: GENITO URINARY SYSTEM AND SEX HORMONES
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 391.5
Logarithm of the Partition Coefficient (xlogp) 4.3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption
The drug is well absorbed from the gastrointestinal tract []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Chemical Identifiers
Formula
C24H25NO4
IUPAC Name
2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
Canonical SMILES
CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4
InChI
InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3
InChIKey
SPIUTQOUKAMGCX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3354
ChEBI ID
CHEBI:5088
CAS Number
15301-69-6
UNII
3E74Y80MEY
DrugBank ID
DB01148
TTD ID
D0ND2J
VARIDT ID
DR00726
ACDINA ID
D00277
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Antagonist [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Flavoxate
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Oxymorphone DM65AGJ Moderate Additive antimotility effects by the combination of Flavoxate and Oxymorphone. Pain [MG30-MG3Z] [5]
Dezocine DMJDB0Y Moderate Additive antimotility effects by the combination of Flavoxate and Dezocine. Pain [MG30-MG3Z] [5]
Coadministration of a Drug Treating the Disease Different from Flavoxate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Moderate Additive antimotility effects by the combination of Flavoxate and Oliceridine. Acute pain [MG31] [5]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Flavoxate and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [6]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Flavoxate and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [6]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Flavoxate and Desipramine. Attention deficit hyperactivity disorder [6A05] [7]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Flavoxate and Cariprazine. Bipolar disorder [6A60] [7]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Flavoxate when combined with Acetylcholine. Cataract [9B10] [8]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Flavoxate and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [9]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Flavoxate and Tiotropium. Chronic obstructive pulmonary disease [CA22] [9]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Flavoxate and Revefenacin. Chronic obstructive pulmonary disease [CA22] [9]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Flavoxate and OPC-34712. Depression [6A70-6A7Z] [7]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Flavoxate and Clomipramine. Depression [6A70-6A7Z] [7]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Flavoxate and Esketamine. Depression [6A70-6A7Z] [10]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Flavoxate and Mepenzolate. Digestive system disease [DE2Z] [7]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Flavoxate and Solifenacin. Functional bladder disorder [GC50] [7]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Flavoxate and Belladonna. Infectious gastroenteritis/colitis [1A40] [7]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Flavoxate and ITI-007. Insomnia [7A00-7A0Z] [7]
R0-93877 DMM4U9G Moderate Antagonize the effect of Flavoxate when combined with R0-93877. Irritable bowel syndrome [DD91] [11]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Flavoxate and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [12]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Flavoxate and Lasmiditan. Migraine [8A80] [13]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Flavoxate and Flibanserin. Mood disorder [6A60-6E23] [14]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Flavoxate when combined with Neostigmine. Myasthenia gravis [8C6Y] [15]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Flavoxate and Phenindamine. Nasopharyngitis [CA00] [7]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Flavoxate and Cyclizine. Nausea/vomiting [MD90] [7]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Flavoxate when combined with Metoclopramide. Nausea/vomiting [MD90] [16]
Polythiazide DMCH80F Minor Altered absorption of Flavoxate due to GI dynamics variation caused by Polythiazide. Oedema [MG29] [17]
Levomethadyl Acetate DM06HG5 Moderate Additive antimotility effects by the combination of Flavoxate and Levomethadyl Acetate. Opioid use disorder [6C43] [18]
Levodopa DMN3E57 Moderate Altered absorption of Flavoxate due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [19]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Flavoxate and Orphenadrine. Parkinsonism [8A00] [7]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Flavoxate and Methylscopolamine. Peptic ulcer [DA61] [7]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Flavoxate and Levomepromazine. Psychotic disorder [6A20-6A25] [7]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Flavoxate and Quetiapine. Schizophrenia [6A20] [7]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Flavoxate and Aripiprazole. Schizophrenia [6A20] [7]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Flavoxate and Iloperidone. Schizophrenia [6A20] [7]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Flavoxate and Paliperidone. Schizophrenia [6A20] [7]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Flavoxate and Molindone. Schizophrenia [6A20] [7]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Flavoxate and Thiothixene. Schizophrenia [6A20] [7]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Flavoxate and Asenapine. Schizophrenia [6A20] [7]
Pramlintide DM0EZ9Q Moderate Altered absorption of Flavoxate due to GI dynamics variation caused by Pramlintide. Type-1/2 diabete [5A10-5A11] [20]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Flavoxate and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [6]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Flavoxate and Acrivastine. Vasomotor/allergic rhinitis [CA08] [7]
⏷ Show the Full List of 40 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Ethyl acrylate E00191 8821 Film/membrane-forming agent; Flavoring agent
Brushite E00392 104805 Diluent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Methyl methacrylate E00133 6658 Film/membrane-forming agent
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Flavoxate Hydrochloride 100mg tablet 100mg Tablet Oral
Flavoxate 100 mg tablet 100 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Flavoxate FDA Label
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res. 1996 Jul 15;727(1-2):91-8.
5 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
6 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
7 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
8 Multum Information Services, Inc. Expert Review Panel.
9 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
10 Cerner Multum, Inc. "Australian Product Information.".
11 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
12 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
13 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
14 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
15 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
16 Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
17 Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
18 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
19 Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
20 Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.